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Abstract
We study the problem of finding the optimal dosage in a phase I clinical trial through the multi-armed
bandit lens. We advocate the use of the Thompson Sampling principle, a flexible algorithm that can
accommodate different types of monotonicity assumptions on the toxicity and efficacy of the doses. For
the simplest version of Thompson Sampling, based on a uniform prior distribution for each dose, we
provide finite-time upper bounds on the number of sub-optimal dose selections, which is unprecedented
for dose finding algorithms. Through a large simulation study, we then show that Thompson Sampling
based on more sophisticated prior distributions outperform state-of-the-art dose identification algorithms
in different types of phase I clinical trials.
Keywords: Multi-Armed Bandits; Phase I Clinical Trials; Thompson Sampling; Bayesian methods.
1. Introduction
Multi-armed bandit models were originally introduced in the 1930’s as a simple model for phase II clin-
ical trials in which one control treatment is tried against one alternative Thompson (1933). While those
models are nowadays widely studied with completely different applications in mind (e.g. online adver-
tisement Chapelle and Li (2011), recommender systems Li et al. (2010) or cognitive radios Anandkumar
et al. (2011)), there has been a surge of interest in using bandits for clinical trials (see Villar et al. (2015)).
In this paper, we focus on phase I clinical trials for single-agent in oncology, for which an adaptation of
the original bandit algorithms could be of interest.
Phase I trials are the first stage of testing in human subjects. Their goal is to evaluate the safety
(and feasibility) of the treatment and identify its side effects. For non-life-threatening diseases, phase I
trials are usually conducted on human volunteers. In life-threatening diseases such as cancer or AIDS,
phase I studies are conducted with patients because of the aggressiveness and possible harmfulness of
the treatments, possible systemic treatment effects, and the high interest in the new drug’s efficacy in
those patients directly. The aim of a phase I dose-finding study is to determine the most appropriate dose
level that should be used in further phases of the clinical trials.
Until recently, cytotoxic agents were the main agent of anti-tumor drug development. A common
assumption for these agents is that both toxicity and efficacy of the treatment are monotonically in-
creasing with the dose Chevret (2006). Hence, only toxicity is required to determine the optimal dose
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which is then the Maximum Tolerated Dose (MTD), defined as the highest dose with acceptable toxic-
ity. From a statistical perspective, the MTD is often defined as the dose level closest to an acceptable
targeted toxicity probability fixed prior to the trial onset Faries (1994); Storer (1989). However, Molec-
ularly Targeted Agents (MTAs) have emerged as a new treatment option in oncology that have changed
the practice of cancer patient care Postel-Vinay et al. (2009); Le Tourneau et al. (2010, 2011, 2012).
Previously-common assumptions do not necessarily hold for MTAs. Although toxicity is still assumed
to be increasing with the dose, it may be so low that the trial cannot be driven by toxicity occurrence only.
Efficacy needs to be studied jointly with toxicity, so that the most appropriate dose is not just the MTD.
In particular, for some mechanisms of action, a plateau of efficacy can be observed when increasing the
dose Hoering et al. (2011), for instance when the targeted receptors are saturated. In this paper, we aim
at providing a unified approach that can be used both for trials involving cytotoxic agents and MTAs.
Phase I cytotoxic clinical trials in oncology involve several ethical concerns. Therefore, in order
to gather information about the dose-toxicity relationship it is not possible to include a large number of
patients and randomize them at each different dose level considered in the trial. Patients treated with dose
levels over the MTD would be exposed to very high toxicity, and patients treated at low dose levels would
be administrated ineffective dose levels. In addition, the total sample size is often very limited. For these
reasons, the doses to be allocated should be selected sequentially, taking into account the outcomes of the
previous allocated doses, with ideally two objectives in mind: finding the MTD (which is crucial for the
next stages of the trial) and treating as many trial participants as possible with this MTD. This trade-off
between treatment (curing patients during the study) and experimentation (finding the best treatment)
is a common issue in clinical trials. By viewing optimal dose identification as a particular multi-armed
bandit problem, this trade-off can be rephrased as a trade-off between rewards and error probability, two
performance measures that are well-studied in the bandit literature and that are known to be somewhat
antagonistic (see (Bubeck et al., 2011; Kaufmann and Garivier, 2017)).
In this paper, we investigate the use of Thompson Sampling (Thompson, 1933), a Bayesian algorithm
that has been successfully used for reward maximization in bandit models, for phase I clinical trial. Our
first contribution is a theoretical study in the context of MTD identification showing that the simplest
version of Thompson based on independent prior distributions for each arm asymptotically minimizes
the number of sub-optimal allocations during the trial. Our second contribution is to show that Thomp-
son Sampling using more sophisticated prior distributions can compete with state-of-the art dose finding
algorithms. We indeed show that the algorithm can exploit the monotonicity assumption on the toxicity
probabilities that are common for MTD identification, but also deal with more complex assumptions on
both the toxicity and efficacy probabilities that are relevant for trials involving MTAs. Through extensive
experiments on simulated clinical trials we show that our Thompson Sampling variants typically outper-
forms state-of-the-art dose finding algorithms. Finally, we propose a discussion revisiting the treatment
versus experimentation tradeoff through a bandit lens, and explain why adaptation of existing best arm
identification designs (Audibert et al., 2010; Karnin et al., 2013) seem currently less promising.
The paper is structured as follows. In Section 2, we present a multi-armed bandit (MAB) model
for the MTD identification problem and introduce the Thompson Sampling algorithm. In Section 3, we
propose an analysis of independent Thompson Sampling: We provide finite-time upper-bounds on the
number of sub-optimal selections, which are matching an (asymptotic) lower bound on those quantities.
Then in Section 4, we show that Thompson Sampling can leverage the usual monotonicity assumptions
in dose-finding clinical trials. In Section 5, we report the results of a large simulation study to assess the
quality of the proposed design. Finally in Section 6, we propose a discussion on the use of alternative
bandit methods.
2
2. Maximum Tolerated Dose Identification as a Bandit Problem
In this section, we propose a simple statistical model for the MTD identification problem in phase I
clinical trial, and show that it can be viewed as a particular multi-armed bandit problem.
A dose finding study involves a number K of dose levels that have been chosen by physicians based
on preliminary experiments (K is usually a number between 3 and 10). Denoting by pk the (unknown)
toxicity probability of dose k, the Maximum Tolerated Dose (MTD) is defined as the dose with a toxicity
probability closest to a target:
k∗ ∈ argmin
k∈{1,...,K}
|θ − pk|,
where θ is the pre-specified targeted toxicity probability (typically between 0.2 and 0.35). For clinical
trials in life-threatening diseases, efficacy is often assumed to be increasing with toxicity, hence the
MTD is the most appropriate dose to further investigate in the rest of the trial. However, we shall see in
Section 4 that under different assumptions the optimal dose may be defined differently.
2.1 A (Bandit) Model for MTD Identification
A MTD identification algorithm proceeds sequentially: at round t a dose Dt ∈ {1, . . . ,K} is selected
and administered to a patient for whom a toxicity response is observed. A binary outcome Xt is revealed
where Xt = 1 indicates that a harmful side-effect occurred and Xt = 0 indicates than no harmful
side-effect occurred. We assume that Xt is drawn from a Bernoulli distribution with mean pDt and
is independent from previous observations. The selection rule for choosing the next dose level to be
administered is sequential in that it uses the past toxicity observations to determine the dose to administer
to the next patient. More formally, Dt is Ft−1-measurable where Ft = σ(D1, X1, . . . , Dt, Xt) is the
σ-field generated by the observations made with the first t patients. Along with this selection rule, a
(Ft-measurable) recommendation rule kˆt indicates which dose would be recommended as the MTD, if
the experiments were to be stopped after t patients.
Usually in clinical trials the total number of patients n is fixed in advance and the first objective is to
ensure that the dose kˆn recommended at the end of the trial is close to the MTD, k∗, but there is also an in-
centive to treat as many patient as possible with the MTD during the trial. LettingNk(t) =
∑t
s=1 1(ks=k)
be the number of time dose k has been given to one of the first t patients, this second objective can be
formalized as that of minimizing Nk(n) for k 6= k∗. In the clinical trial literature, empirical evaluations
of dose finding designs usually report both the empirical distribution of the recommendation strategy
kˆn (that should be concentrated on the MTD) and estimates of E[Nk(n)]/n for all dose k to assess the
quality of the selection strategy in terms of allocating MTD as often as possible.
The sequential interaction protocol described above is reminiscent of a stochastic multi-armed bandit
(MAB) problem (see Lattimore and Szepesvari (2018) for a recent survey). A MAB model refers to a
situation in which an agent sequentially chooses arms (here doses) and gets to observe a realization of
an underlying probability distribution (here a Bernoulli distribution with mean being the probability that
the chosen dose is toxic). Different objectives have been considered in the bandit literature, but most of
them are related to learning the arm with largest mean, whereas in the context of clinical trials we are
rather concerned with the arm which is the closest to some threshold.
2.2 Thompson Sampling for MTD Identification
Early works on bandit models (Robbins, 1952; Lai and Robbins, 1985) mostly consider a reward max-
imization objective: The samples (Xt) are viewed as rewards, and the goal is to maximize the sum of
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these rewards, which boils down to choosing the arm with largest mean as often as possible. This prob-
lem was originally introduced in the 1930s in the context of phase II clinical trials (Thompson, 1933). In
this context, each arm models the response to a particular treatment, and maximizing rewards amounts
to giving the treatment with largest probability of success to as many patients as possible. This suggests
a phase II trial is designed for treating as many patients as possible with the best treatment rather than
identifying it. The trade-off between treatment and identification is also relevant for MTD identification:
besides finding the MTD another objective is to treat as many patients as possible with it during the trial.
Reward maximization in a Bernoulli bandit model is a well-understood problem. In particular, it is
known since (Lai and Robbins, 1985) that any algorithm that performs well on every bandit instance
should select each sub-optimal arm k more than Ck log(n) times, where Ck is some constant, in a
regime of large values of n. Algorithms with finite-time upper bounds on the number of sub-optimal
selections have been exhibited (Auer et al., 2002; Audibert et al., 2009), some of which are matching the
aforementioned lower bound on the number of sub-optimal selections (Cappe´ et al., 2013). In the context
of MTD identification, we are also concerned about minimizing the number of sub-optimal selections
but with a different notion of optimal arm: the MTD instead of the arm with largest mean.
Algorithm for maximizing rewards in a bandit model mostly fall in two categories: frequentist al-
gorithms, based on upper-confidence bounds (UCB) for the unknown means of the arms (first proposed
by Katehakis and Robbins (1995); Auer et al. (2002)) and Bayesian algorithms, that exploit a posterior
distribution on the means (see, e.g. Kaufmann et al. (2012a)). Among those, Thompson Sampling (TS,
(Thompson, 1933)) is a popular approach, known for its practical successes beyond simple bandit prob-
lems (Agrawal and Goyal, 2013b; Agrawal and Jia, 2017).Variants of Thompson Sampling have been
notably studied for phase II clinical trials involving two treatments (see Thall and Wathen (2007) and
references therein). Some theoretical properties have also been established for this algorithm, showing in
particular that it is asymptotically matching the Lai and Robbins lower bound in Bernoulli bandit models
(Kaufmann et al., 2012b; Agrawal and Goyal, 2013a).
Thompson Sampling, also known as probability matching, implements the following simple Bayesian
heuristic. Given a prior distribution over the arms, at each round an arm is selected at random according
to its posterior probability of being optimal. In this paper, we advocate the use of Thompson Sampling
for dose finding, using the appropriate notion of optimality. In particular, Thompson Sampling for MTD
identification consists in selecting a dose at random according to its posterior probability of being the
MTD. Given a prior distribution Π0 on the vector of toxicity probabilities, p = (p1, . . . , pK) ∈ [0, 1]K ,
a posterior distribution Πt can be computed by taking into account the first t observations. A possible
implementation of Thompson Sampling consists of drawing a sample θ(t) = (θ1(t), . . . , θK(t)) from
the posterior distribution Πt and selecting at round t+ 1 the dose that is the MTD in the sampled model:
Dt+1 = argmink |θk(t) − θ|. There are several possible choices for the recommendation rule kˆt, which
are discussed in the upcoming sections.
We first study in the next section the most simple variant of this algorithm, based on a uniform prior
distribution over each arm, and later propose the use of more sophisticated prior distributions.
3. Independent Thompson Sampling: an Asymptotically Optimal Algorithm
Inspired by the bandit literature, we introduce the simplest version of Thompson Sampling, that assumes
independent uniform prior distributions on the probability of toxicity of each dose. We refer to this algo-
rithm as Independent Thompson Sampling and propose some theoretical guarantees for this algorithm.
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3.1 The Algorithm
The prior distribution on p = (p1, . . . , pK) is Π0 =
⊗K
i=1 pi
0
k, where pi
0
k = U([0, 1]) is a uniform
distribution. Letting pitk be the posterior distribution of pk given the observations from the first t patients,
the posterior distribution also has a product form, Πt =
⊗K
i=1 pi
t
k. The posterior distribution on each arm
can further be made explicit: pitk is a Beta distribution, more precisely Beta(Sk(t)+1, Nk(t)−Sk(t)+1)
where Sk(t) =
∑t
s=1Xs1(As=k) is the sum of rewards obtained from arm k and As is the arm pulled at
time s.
The selection rule of Independent Thompson Sampling is simple: a sample from the posterior distri-
bution on the toxicity probability of each dose is generated, and the dose for which the sample is closest
to the threshold is selected: { ∀k ∈ {1,K}, θk(t) ∼ pitk
Dt+1 = argmink |θk(t)− θ|.
Several recommendation rules may be used for Independent Thompson Sampling. As the randomization
induces some exploration, recommending kˆt = Dt+1 is not a good idea. Inspired by what is proposed
by Bubeck et al. (2011) for assigning a recommendation rule to rewards maximizing algorithms, a first
idea is to recommend kˆt = argmink |µˆk(t) − θ|, where µˆk(t) is the empirical mean of dose k after
the t-th patient of the study. Leveraging the fact that TS is supposed to allocate the MTD most of the
time, another idea is to either select kˆt = argmaxk Nk(t) or to pick kˆt uniformly at random among the
allocated doses.
3.2 Control of the Number of Sub-Optimal Selections
For the classical rewards maximization problem, the first finite-time analysis of Thompson Sampling for
Bernoulli bandits dates back to Agrawal and Goyal (2012) and was further improved by Kaufmann et al.
(2012b); Agrawal and Goyal (2013a). In Appendix A, building on the analysis of Agrawal and Goyal
(2013a), we prove the following for Thompson Sampling applied to MTD identification.
Theorem 1 Introducing for every k 6= k∗ the quantity
d∗k := argmin
d∈{pk∗ ,2θ−pk∗}
|pk − d|,
Independent Thompson Sampling satisfies the following. For all  > 0, there exists a constant C,θ,p
(depending on , the threshold θ and the toxicity probabilities) such that
∀k : |pk − θ| 6= |θ − pk∗ |,
E[Nk(n)] ≤ 1 + 
kl(pk, d
∗
k)
log(n) + C,θ,p,
Theorem 1 shows that the total number of allocations to a sub-optimal dose in a trial involving n
patient is logarithmic in n, which justifies that the MTD is given most of the time, at least for large
values of n as the constant in front of log(n) can be large. The lower bound given in Theorem 2 below
furthermore shows that Independent Thompson Sampling actually achieves the minimal number of sub-
optimal allocations when n grows large.
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Theorem 2 We define a uniformly efficient design as a design satisfying for all possible toxicity proba-
bilities p, for all α ∈]0, 1[, for all k : |θ − pk| 6= |θ − pk∗ |, E[Nk(n)] = o(nα) when n goes to infinity.
Any uniformly efficient design satisfies
lim inf
n→∞
E[Nk(n)]
log(n)
≥ 1
kl(pk, d
∗
k)
,
and kl(x, y) = x log(x/y) + (1− x) log((1− x)/(1− y)) is the binary Kullback-Leibler divergence.
Theorem 2 is a counterpart of the Lai and Robbins lower bound for classic bandits (Lai and Robbins,
1985). It shows that a MTD identification procedure that behaves well in terms of sub-optimal selec-
tions should at least select each sub-optimal dose logarithmically. Its proof follows standard change-of-
measure arguments (see Garivier et al. (2016)).
3.3 Control of the Error Probability
If the recommendation rule kˆn consists of selecting uniformly at random a dose among the doses that
were allocated during the trial, {D1, . . . , Dn}, it follows from Theorem 1 that
P
(
kˆn 6= k∗
)
=
∑
k 6=k∗
E[Nk(n)]
n
≤ D ln(n)
n
, (1)
where D is a (possibly large) problem-dependent constant. Hence finite-time upper bounds on the num-
ber of sub-optimal selection lead to non-asymptotic upper bound on the error probability of the design.
Note that for the state-of-the-art dose-finding designs it is not known whether such results can be ob-
tained; the only results available provide conditions for consistency. For example Shen and O’Quigley
(1996); Cheung and Chappell (2002) exhibit some conditions on the toxicity probabilities under which a
classical design called the CRM is such that kˆn converges almost surely to k∗.
This being said, the upper bound (1) is not very informative, as a very large number of patients is
needed to have is at least smaller than 1, and one could expect to have an upper bound that is expo-
nentially decreasing with n. As we shall see in Section 6, an adaptation of a best arm identification
algorithm (Karnin et al., 2013) leads to such an upper bound, but may be less desirable for clinical trials
from an ethical point of view. This is why we rather chose to investigate in what follows several variants
of Thompson Sampling coupled with an appropriate recommendation rule.
By using uniform and independent priors on each toxicity probability, Independent Thompson Sam-
pling is the simplest possible implementation of Thompson Sampling. We now explain that using a more
sophisticated prior distribution allows the algorithm to leverage some particular constraints of the dose
finding problem, like increasing toxicities or a plateau of efficacy.
4. Exploiting Monotonicity Constraints with Thompson Sampling
Independent Thompson Sampling is an adaptation of a state-of-the-art bandit algorithm for identifying
the MTD that does not leverage any prior knowledge on (e.g.) the ordering of the arms’ means. While
it can be argued that when testing drugs combinations, no natural ordering between the doses exists
(see, e.g., Mozgunov and Jaki (2017)), in most cases some monotonicity assumptions can speed up the
learning process.
A typical assumption in phase I studies is that both efficacy and toxicity are increasing with the
dose. We show in Section 4.1 that Thompson Sampling using an appropriate prior is competitive to
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state-of-the-art approaches leveraging the monotonicity. In Section 4.2, we further show that Thompson
Sampling is a flexible method that can be useful under more complex monotonicity assumptions. More
specifically, we show it can also handle an efficacy “plateau,” where efficacy may be non-increasing after
a certain dose level.
4.1 Thompson Sampling for Increasing Toxicities
In a phase I study in which both toxicity and efficacy are increasing with the dose, the MTD is the
most relevant dose to allocate in further stages. Assuming p1 ≤ · · · ≤ pk, we now focus on algorithms
leveraging this extra information. To exploit this structure, escalation procedures have been developed
in the literature, the most famous being the “3+3” design Storer (1989). In this design, adjusted for
θ = 0.33, the lowest dose is first given to 3 patients. If no patient experiences toxic effects, one escalates
to the next dose and repeats the process. If one patient experiences toxicity, the dose is given to 3
more patients, and if less than two patients among the 6 experience toxicity, one escalates to the next
dose. Otherwise the trial is stopped, which is also the case if from the beginning 2 out of the 3 patients
experience a toxic effect. Upon stopping, the previous dose is recommended as the MTD, or all doses
are decided too toxic if one stops at the first dose level. Although it is clear that the guarantees in terms
of error probability (or sub-optimal selections) are very weak, “3+3” is still often used in practice.
Alternative to this first design are variants of the Continuous Reassessment Method (CRM), proposed
by O’Quigley et al. (1990). The CRM uses a Bayesian model that combines a parametric dose/toxicity
relationship with a prior on the model parameters. Under this model, CRM appears as a greedy strategy
that selects at each round the dose whose expected toxicity under the posterior distribution is closest to
the threshold. We propose in this section several variants of Thompson Sampling based on the same
Bayesian model, but that favor (slightly) more exploration.
A Bayesian model for increasing toxicities In the CRM literature, several parametric models that
yield an increasing toxicity have been considered. In this paper, we choose a two-parameter logistic
model that is among the most popular. Under this model, each dose k is assigned an effective dose uk
(that is usually not related to a true dose expressed in a mass or volume unit) and the toxicity probability
of dose k is given by
pk(β0, β1) = ψ(k, β0, β1),
where ψ(k, β0, β1) =
1
1 + e−β0−β1uk
.
A typical choice of prior is
β0 ∼ N (0, 100) and β1 ∼ Exp(1).
It is worth noting that this model also heavily relies on the effective doses u1, . . . , uK that are usually
chosen depending on some prior toxicities set by physicians, p01 ≤ p02 ≤ · · · ≤ p0K . Letting β0, β1 be the
prior mean of each parameter, the effective doses are calibrated such that for all k, ψ(k, β0, β1) = p0k. If
there is no medical prior knowledge about the toxicity probabilities, some heuristics for choosing them
in a robust way have been developed (see Chapter 9 of Cheung (2011)).
Under this model, given some observations from the different doses one can compute the posterior
distribution over the parameters β0 and β1; that is, the conditional distribution of these parameters given
the observations. Although there is no closed form for these posterior distributions, they can be easily
sampled from using Hamiltonian Monte-Carlo Markov Chain algorithms (HMC) as the log-likelihood
under these models is differentiable. In practice, we use the Stan implementation of these Monte-Carlo
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sampler (Stan Development Team, 2015), and use (many) samples to approximate integrals under the
posterior when needed.
4.1.1 THOMPSON SAMPLING
Thompson Sampling selects a dose at random according to its posterior probability of being the MTD.
Under the two-parameter Bayesian logistic model presented above, letting pit denote the posterior distri-
bution on (β0, β1) after the first t observations, the posterior probability that dose k is the MTD is
qk(t) := P
(
k = argmin
`
|θ − p`(β0, β1)|
∣∣∣∣Ft)
=
∫
R
1
(
k = argmin
`
|θ − p`(β0, β1)|
)
dpit(β0, β1).
A first possible implementation of Thompson Sampling that we use in our experiments consists of
computing approximations qˆk(t) of the probabilities qk(t) (using posterior samples) and selecting at
round t + 1 a dose Dt+1 ∼ qˆ(t), i.e. such that P (Dt+1 = k|Ft) = qˆk(t). A second implementation
of Thompson Sampling (that may be computationally easier) consists of drawing one sample from the
posterior distribution of (β0, β1), and selecting the MTD in the sampled model:(
β˜0(t), β˜1(t)
)
∼ pit,
DTSt+1 ∈ argmin
k∈{1,...,K}
∣∣∣θ − pk (β˜0(t), β˜1(t))∣∣∣ . (2)
It is easy to see that this algorithm concides with Thompson Sampling in that P
(
DTSt+1 = k|Ft
)
= qk(t).
We will present below a variant of Thompson Sampling based on the first implementation (TS A) and a
variant based on the second implementation (TS()).
Due to the randomization, Thompson Sampling performs more exploration than the “greedy” CRM
(O’Quigley et al., 1990) method, which selects at time t the MTD under the model parameterized by
(βˆ0, βˆ1), the posterior means of the two parameters, given by
βˆ0(t) =
∫
R
β0dpit(β0, β1) and βˆ1(t) =
∫
R
β1dpit(β0, β1). (3)
More formally, the sampling rule of the CRM is
DCRMt+1 ∈ argmin
k∈{1,...,K}
∣∣∣θ − pk(βˆ0(t), βˆ1(t))∣∣∣ .
The recommendation rule for CRM after t patients is identical to the next dose that would be sampled
under this design, that is kˆCRMt = D
CRM
t+1 . However, as Thompson Sampling is more exploratory, we
propose the use of the recommendation rule kˆTSt = argmink |θ− pk(βˆ0(t), βˆ1(t))|, which coincides with
the recommendation rule of the CRM.
4.1.2 TWO VARIANTS OF THOMPSON SAMPLING
The randomized aspect of Thompson Sampling makes it likely to sample from large or small doses, with-
out respecting some ethical constraints of phase I clinical trials. Indeed, patients should not be exposed
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to too-high dose levels; overdosing should be controlled. Hence, we also propose two “regularized”
versions of TS. The first depends on a parameter  > 0 set by the user that ensures that the expected
toxicity of the recommended dose remains within  of the toxicity of the empirical MTD. The second
restricts the doses to be tested to a set of admissible doses. These algorithms are formally defined below,
and their performance is evaluated in Section 5.
TS() We first compute βˆ0(t), βˆ1(t) from (3) as well as toxicity of the dose that is closest to θ under
this model (that is the toxicity of the dose selected by the CRM):
pˆ(t) = pkˆt(βˆ0(t), βˆ1(t)), with kˆt = argmin
k
∣∣∣θ − pk(βˆ0(t), βˆ1(t))∣∣∣
Next we sample β˜0(t), β˜1(t) from the posterior distribution pit and select a candidate dose level Dt+1
using (2). If the predicted toxicity level pDt+1(βˆ0(t), βˆ1(t)) is not in the interval (pˆ(t) − , pˆ(t) + ),
then we reject our values of β˜0(t), β˜1(t), draw a new sample from pit and repeat the process. In order to
guarantee that the algorithm terminates, we only reject up to 50 samples, after which we use the sample
that gives the dose with minimum toxicity among all 50 samples.
TS A We introduce the TS A algorithm, which enforces the selected dose to be in some set At,
sampling from the distribution
P (Dt+1 = k|Ft) =
qˆk(t)1(k∈At)∑
`∈At qˆ`(t)
,
where At is the set of admissible doses after t rounds meeting the following two criteria:
1. dose k has either already been tested, or is the next-smallest dose which has not yet been tested
2. the posterior probability that the toxicity of dose k exceeds the toxicity of the dose closest to θ is
smaller than some threshold:
P
(
ψ(k, β0, β1) > ψ(k
′, β0, β1),wherek′ = argmin
k′∈{1,...,K}
∣∣θ − ψ(k′, β0, β1)∣∣
∣∣∣∣∣Ft
)
≤ c1.
At is inspired by the admissible set of Riviere et al. (2017) described in detail in the next section.
4.2 Thompson Sampling for Efficacy Plateau Models
In some particular trials, it has been established that efficacy is not always increasing with the dose.
Motivated by some concrete examples discussed in their paper, Riviere et al. (2017) consider a model
in which the dose effectiveness can plateau after some unknown level, while toxicity still increases with
dose level. In these models, MTD identification is no longer relevant and the objective is rather to identify
the smallest dose with maximal efficacy and with toxicity no more than θ. More formally, introducing
effk the efficacy probability of dose k, the objective is to identify
k∗ = min
{
k : effk = max
`:p`≤θ
eff`
}
In a dose finding study involving efficacy, at each time step t a doseDt is allocated to the t-th patient,
and the toxicity Xt is observed, as well as the efficacy Yt. With these two-dimensional observations, it
is less clear how to define a notion of reward, as in the previous case. However as we shall see, the
Thompson Sampling approach, initially introduced for reward maximization in bandit models, can also
be applied here, and it bears some similarities to the method developed by Riviere et al. (2017).
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A Bayesian model for toxicity and efficacy Thompson Sampling requires a Bayesian model for both
the dose/toxicity and the dose/efficacy relationship that enforces an increasing toxicity and a increasing
then plateau efficacy. We will use the model proposed by Riviere et al. (2017), that we now describe.
Under this model, toxicity and efficacy are assumed to be independent. The (increasing) toxicity
follows the two-dimensional Bayesian logistic model with effective doses uk:
pk = pk(β0, β1) = ψ(k, β0, β1)
and β0 ∼ N (0, 100), β1 ∼ Exp(1).
Efficacy also follows a logistic model, with an additional parameter τ that indicates the beginning of the
plateau. The efficacy probability of dose level k is
effk = effk(γ0,γ1, τ) = φ(k, γ0, γ1, τ), with (4)
φ(k, γ0, γ1, τ) :=
1
1 + e−[γ0+γ1(vk1(k<τ)+vτ1(k≥τ))]
,
where vk is the effective efficacy of dose k. Given (t1, . . . , tK) such that
∑K
i=1 ti = 1, a probability dis-
tribution on {1, . . . ,K}, the three parameters (γ0, γ1, τ) are independent and drawn from the following
prior distributions:
γ0 ∼ N (0, 100), γ1 ∼ Exp(1), τ ∼ (t1, . . . , tK).
The prior on τ may be provided by a physician or set to (1/K, . . . , 1/K) in case one has no prior
information. Just like the effective doses uk (that we may now call effective toxicities), the effective
efficacies vk are calculated using prior efficacies eff01 ≤ · · · ≤ eff0K :
vk =
(
log
(
eff0k
1− eff0k
)
− γ0
)/
γ1,
where γ0 = 0 and γ1 = 1 are the prior means of the parameters γ0 and γ1.
Generating samples from the posterior distribution of (γ0, γ1, τ) is a bit more involved than it was
for (β0, β1) as it cannot be handled directly with HMC given that (γ0, γ1) are continuous and τ is dis-
crete. Thus, we proceed in the following way: we first draw samples from p(γ0, γ1|Defft ), which can be
performed with HMC (and requires marginalizing out the discrete parameter τ , following the example
of change point models given in the Stan manual (Stan Development Team, 2015)). Then we sample τ
conditionally to γ0, γ1,Defft .
4.2.1 THOMPSON SAMPLING
Recall that the principle of Thompson Sampling is to randomly select doses according to their posterior
probability of being optimal. This idea can also be applied in this more complex model, using the corre-
sponding definition of optimality. Given a vector ψ = (ψ1, . . . , ψK) of increasing toxicity probabilities
and a vector φ = (φ1, . . . , φK) of increasing then plateau efficacy probabilities, the optimal dose is
Opt(ψ,φ) := min
{
k : φk = max
`:ψ`≤θ
φ`
}
. (5)
The posterior probability of dose k to be optimal in that case is
qk(t) := P (k = Opt (ψ(·, β0, β1), φ(·, γ0, γ1, τ))| Ft)
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and in our experiments, we implement Thompson Sampling by computing approximations qˆk(t) from
the quantities qk(t) (based on posterior samples) and then selecting a dose Dt+1 ∼ qˆ(t) where qˆ(t) =
(qˆ1(t), . . . , qˆK(t)). Just like in the previous model, an alternative implementation of Thompson Sam-
pling would sample parameters from their posterior distributions and select the optimal dose in this
sampled model. More formally, letting
β˜0(t), β˜1(t) and γ˜0(t), γ˜1(t), τ˜(t), (6)
be samples from the posterior distributions after t observations of the toxicity and efficacy parameters
respectively, one can compute ψ˜k(t) = ψ(k, β˜0(t), β˜1(t)) and φ˜k(t) = φ(k, γ˜0(t), γ˜1(t), τ˜(t)) for every
dose k. Given the toxicity and efficacy vectors
ψ˜(t) =
(
ψ˜1(t), . . . , ψ˜K(t)
)
and φ˜(t) =
(
φ˜1(t), . . . , φ˜K(t)
)
,
this implementation of Thompson Sampling selects at round t+ 1 DTSt+1 = Opt
(
ψ˜(t), φ˜(t)
)
.
Recommendation rule. Here also we expect Thompson Sampling to be too exploratory for dose rec-
ommendation. Hence, we base our recommendation on estimated values. Given the posterior means
βˆ0(t), βˆ1(t), γˆ0(t), γˆ1(t) (obtained based on posterior samples) and τˆ(t) the mode of the posterior distri-
bution of the breakpoint (see the next section for its computation), we compute ψˆk(t) = ψ(k, βˆ0(t), βˆ1(t))
and φˆk(t) = φ(k, γˆ0(t), γˆ1(t), τˆ(t)) and recommend kˆt = Opt
(
ψˆ(t), φˆ(t)
)
.
4.2.2 A VARIANT OF THOMPSON SAMPLING USING ADAPTIVE RANDOMIZATION
Interestingly, the need for randomization in the context of plateau efficacy has already been observed by
Riviere et al. (2017). More precisely, as we explain below, the algorithm MTA-RA described in that
work can be viewed as an hybrid approach between Thompson Sampling and a CRM approach.
Additionally to the use of adaptive randomization, the MTA-RA algorithm also introduces a notion
of the admissible set. The set of admissible doses after t patients, denoted byAt, is the set of dose levels
k meeting all of the following criteria:
1. dose k has either already been tested, or is the next-smallest dose which has not yet been tested
2. the posterior probability that the toxicity of dose k exceeds θ is smaller than some threshold:
P (ψ(k, β0, β1) > θ|Ft) ≤ c1 (7)
3. if the dose has been tested more than 3 times, the posterior probability that the efficacy is larger
than ξ is larger than some threshold:
P (φ(k, γ0, γ1, τ) > ξ|Ft) ≥ c2 (8)
Practical computation of the admissible set can be performed using posterior samples from (β0, β1) to
check the criterion (7) and posterior samples from (γ0, γ1, τ) to check the criterion (8).
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The MTA-RA algorithm works in two steps. The first step exploits the posterior distribution of the
breakpoint, tk(t) := P
(
τ = k|Defft
)
, and uses randomization to pick a value τˆ(t) close to the mode of
this distribution. More precisely, given (tˆk(t))k=1,...,K an estimate of the posterior distribution of τ , let
Rt :=
{
k :
∣∣∣∣ max1≤`≤K(tˆ`(t))− tˆk(t)
∣∣∣∣ ≤ s1, 1 ≤ k ≤ K}
be a set of candidate values for the position of the breakpoint. Then under MTA-RA,
P (τˆ(t) = k|Ft) =
tˆk(t)1(k∈Rt)∑
`∈Rt tˆ`(t)
.
The threshold s1 is often adapted such that it is larger in the beginning of the trial when we have high
uncertainty about the estimates, but it grows smaller as the trial continues. The second step of MTA-
RA doesn’t employ randomization. Based on posterior samples from (γ0, γ1) conditionally to τ being
equal to the sampled value τˆ(t), efficacy estimates φˆk are produced (taking the mean of the values of
φ(k, γ˜0, γ˜1, τˆ(t)) for many samples γ˜0, γ˜1) and finally the selected dose is
DMTA-RAt+1 = inf
{
k ∈ At : φˆk = max
j∈At
φˆj
}
.
If τˆ(t) were replaced by a point estimate (e.g. the mode of the breakpoint posterior distribution tˆ(t)),
MTA-RA would be close to a CRM approach that computes estimates of all the parameters and acts
greedily with respect to those estimated parameters (with the additional constraint that the chosen dose
has to remain in the admissible set). However, the first step of MTA-RA bears similarities with the first
step of a Thompson Sampling implementation that would sample a parameter τ from the tˆ(t) (and later
sample the other parameters conditionally to that value and act greedily in the sampled model). The
difference is the use of adaptive randomization, in which the sample is not exactly drawn from tˆ(t), but
is constrained to fall in some set (hereRt) that depends on previous observations.
The TS A algorithm. We believe that using adaptive randomization is a good idea to control the
amount of exploration performed by Thompson Sampling, which leads us to propose the TS A algo-
rithm, that incorporates the constraint to select a dose that belongs to the admissible set At. More
formally, TS A selects a dose at random according to
P (Dt+1 = k|Ft) =
qˆk(t)1(k∈At)∑
`∈At qˆ`(t)
,
where we recall that qˆk(t) is an estimate of the posterior probability that dose k is optimal. Compared
to the variant of TS A for increasing toxicities that is proposed in Section 4.1, the difference here is the
appropriate definition of the admissible set, that involves both toxicity and efficacy probabilities.
Practical remark. Approximations tˆk(t) of the breakpoint distribution can be computed using that
tk(t) = tk
∫
L(Defft |γ0, γ1, k)∑K
s=1 tsL(Defft |γ0, γ1, s)
p(γ0, γ1|Defft )dγ0dγ1,
where L(Defft |γ0, γ1, s) is the likelihood of the efficacy observations when the efficacy model parame-
ters are (γ0, γ1, s) and p(γ0, γ1|Defft ) is the density of the distribution of (γ0, γ1) given the observations.
tˆk(t) can be thus be obtained by Monte-Carlo estimation based on samples from p(γ0, γ1|Defft ).
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5. Experimental Evaluation
We now present an empirical evaluation of the variants of Thompson Sampling introduced in the paper
first in the context of increasing efficacy and then with the presence of a plateau of efficacy. In both
groups of experiments, we adjusted our designs to some common practices in phase I clinical trials. We
used a start-up phase for all designs (starting from the smallest dose and escalating until the first toxicity
is observed) and we also used cohorts of patients of size 3. This means that the same dose is allocated to
3 patients at a time and the model is updated after seeing the outcome for these 3 patients.
5.1 MTD Identification
In this set of experiments, we evaluate the performance of the three algorithms introduced in Section 4.1,
TS, TS() and TS A, and compare them to the 3+3 and CRM baseline. We experiment with the value
 = 0.05 for TS() and set the parameter of TS A to c1 = 0.8. We also include Independent TS as
proposed in Section 2, which is agnostic to the increasing structure.
In Tables 1 and 2 we provide results for nine different scenarios in which there are K = 6 doses with
a target toxicity θ = 0.30, budget n = 36 and prior toxicities
p = [0.06 0.12 0.20 0.30 0.40 0.50].
For each scenario and algorithm, we report the percentage of allocation to each dose and the percentage
of the recommendations of each dose when n = 36, estimated over N = 2000 repetitions. For the 3+3
design, only the recommendation percentages are displayed, as the percentage of allocations would be
computed based on a number of patients smaller than 36 (as a 3+3 based trial involves some random
stopping). This design is also the only one that would stop and recommend none of the doses if they are
all judged too toxic: we add this fraction of no recommendation in the table.
For each scenario (corresponding to different increasing toxicity probabilities) the MTD is underlined
and we mark in bold the fraction of recommendation or allocation of the MTD that are superior to what
is achieved by the CRM. We now comment on the performance of the algorithms on those scenarios.
Dose recommendation. TS() outperforms CRM 6 out of 9 times, while TS A does so 5 out of
9 times. As expected, Independent TS, which does not leverage the increasing structure, does not
have a remarkable performance. This algorithm would need a larger budget to have a good empirical
performance. With n = 36 in most cases this strategy is not doing much better than selecting the doses
uniformly at random. One can also observe that the 3+3 design (that may however require less than 36
patients in the trial) performs very bad in terms of dose recommendation.
Dose allocation. While TS A and TS() do not always have higher allocation percentage at the opti-
mal (underlined) dose compared to CRM, a scan of the dose allocation results in Table 1 and 2 shows
that the addition of the admissible setA and  regularity to the Thompson Sampling method consistently
reduces the allocation percentage of higher toxicity doses. TS A performs best in this regard (it is more
cautious with allocating higher doses) across all algorithms (e.g. it consistently has superior performance
compared to CRM), while TS() has comparable performance with CRM. We believe this result is of
interest in trials where toxicity is an ethical concern.
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Table 1: Results for MTD identification
Algorithm Recommended Allocated
1 2 3 4 5 6 1 2 3 4 5 6
Sc. 1: Toxicity probabilities 0.30 0.45 0.55 0.60 0.75 0.80 0.30 0.45 0.55 0.60 0.75 0.80
3 + 3 (32.3) 35.0 20.8 7.8 3.6 0.5 0.05 - - - - - -
CRM 77.2 20.7 1.9 0.2 0.0 0.0 70.1 21.7 6.2 1.5 0.3 0.3
TS 77.9 20.4 1.7 0.1 0.0 0.0 66.4 19.5 6.1 2.2 1.1 4.8
TS() 76.8 21.3 1.8 0.1 0.0 0.0 70.0 22.1 6.2 1.2 0.2 0.3
TS A 79.8 18.2 1.7 0.2 0.1 0.0 76.3 19.7 3.5 0.5 0.1 0.0
Independent TS 36.5 30.2 16.7 12.5 2.6 1.5 22.8 21.6 17.5 15.9 11.4 10.7
Sc. 2: Toxicity probabilities 0.05 0.12 0.15 0.30 0.45 0.50 0.05 0.12 0.15 0.30 0.45 0.50
3 + 3 (1.1) 5.6 6.75 21.4 29.5 18.5 17.3 - - - - - -
CRM 0.3 1.3 17.1 53.9 21.7 5.9 10.3 10.7 20.6 29.9 15.9 12.7
TS 0.0 1.7 15.7 48.6 26.3 7.7 13.8 13.9 18.3 20.7 12.7 20.6
TS() 0.2 1.3 16.2 53.4 23.0 5.9 10.3 10.2 19.6 30.8 16.8 12.3
TS A 0.0 1.8 14.9 44.3 24.9 14.1 15.3 19.5 25.7 23.9 10.2 5.5
Independent TS 18.2 18.5 19.9 19.9 11.8 11.7 15.8 18.7 18.9 17.8 14.6 14.2
Sc. 3: Toxicity probabilities 0.01 0.03 0.07 0.11 0.15 0.30 0.01 0.03 0.07 0.11 0.15 0.30
3 + 3 (0.05) 0.3 1.6 3.8 5.8 22.0 66.6 - - - - - -
CRM 9.6 0.0 0.1 1.3 14.8 74.1 14.0 8.2 8.9 8.7 14.8 45.4
TS 3.3 0.0 0.2 1.4 15.1 80.0 11.8 9.1 9.8 11.4 14.6 43.3
TS() 2.8 0.0 0.1 1.4 13.8 82.0 11.2 8.2 8.9 9.0 15.3 47.4
TS A 2.5 0.0 0.1 1.7 14.3 81.5 11.7 10.6 13.6 15.9 16.0 32.1
Independent TS 19.0 8.8 13.1 16.8 21.1 21.3 15.3 16.1 16.9 17.1 17.8 16.7
Sc. 4: Toxicity probabilities 0.10 0.20 0.30 0.40 0.47 0.53 0.10 0.20 0.30 0.40 0.47 0.53
3 + 3 (3.15) 12.8 20.85 25.3 17.1 11.4 9.4 - - - - - -
CRM 1.2 22.0 42.2 25.7 6.9 2.1 14.6 23.1 30.6 18.0 7.4 6.3
TS 1.3 16.5 42.8 27.7 8.7 3.1 21.1 20.5 21.0 14.0 7.1 16.3
TS() 1.5 20.6 43.3 25.2 7.0 2.3 14.8 22.5 30.5 17.8 7.8 6.6
TS A 1.3 20.6 42.3 22.2 9.0 4.4 25.1 31.0 27.4 11.9 3.2 1.3
Independent TS 17.7 21.9 20.9 18.4 12.3 8.8 16.3 19.5 18.6 17.0 15.0 13.6
Sc. 5: Toxicity probabilities 0.10 0.25 0.40 0.50 0.65 0.75 0.10 0.25 0.40 0.50 0.65 0.75
3 + 3 (4.1) 18.9 31.2 25.3 15.3 4.3 1.0 - - - - - -
CRM 4.8 49.7 39.0 6.5 0.1 0.0 17.8 38.3 30.9 9.0 2.4 1.7
TS 3.5 51.0 40.7 4.5 0.3 0.0 26.0 31.4 22.8 8.5 3.0 8.3
TS() 4.3 51.5 38.0 5.8 0.4 0.1 17.2 38.5 31.3 8.9 2.4 1.6
TS A 3.0 50.8 36.4 7.0 1.6 1.1 29.6 40.1 23.4 6.1 0.8 0.1
Independent TS 24.9 31.6 21.6 14.6 5.1 2.2 19.2 22.7 19.2 16.3 12.3 10.3
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Table 2: Results for MTD identification (continued)
Algorithm Recommended Allocated
1 2 3 4 5 6 1 2 3 4 5 6
Sc. 6: Toxicity probabilities 0.08 0.12 0.18 0.25 0.33 0.39 0.08 0.12 0.18 0.25 0.33 0.39
3 + 3 (2.25) 5.5 10.4 14.9 18.4 18.3 30.4 - - - - - -
CRM 0.3 1.3 10.6 29.1 31.2 27.5 11.7 10.7 16.2 19.5 18.2 23.7
TS 0.3 1.8 10.7 26.6 29.6 31.0 15.6 13.1 14.7 14.9 12.1 29.5
TS() 0.4 1.7 11.6 28.7 31.3 26.3 11.6 10.5 17.3 18.8 18.7 23.1
TS A 0.1 1.9 12.0 28.5 26.5 31.0 17.5 21.1 24.7 19.3 8.9 8.5
Independent TS 14.5 17.1 19.2 17.3 17.3 14.7 14.9 17.9 17.8 17.3 16.3 15.8
Sc. 7: Toxicity probabilities 0.15 0.30 0.45 0.50 0.60 0.70 0.15 0.30 0.45 0.50 0.60 0.70
3 + 3 (8.1) 26.5 30.6 18.3 11.5 3.9 1.3 - - - - - -
CRM 16.9 59.4 20.4 3.0 0.2 0.2 27.7 40.8 22.4 6.0 1.8 1.4
TS 13.2 57.4 25.8 3.5 0.1 0.2 34.6 31.2 17.0 6.4 2.8 8.0
TS() 14.7 61.3 19.6 4.0 0.4 0.1 26.7 41.9 21.4 6.5 1.8 1.7
TS A 13.7 59.5 21.5 3.7 0.9 0.7 41.7 39.3 15.5 3.1 0.4 0.1
Independent TS 23.7 32.6 19.2 13.7 7.3 3.4 19.1 22.4 17.8 16.2 13.3 11.2
Sc. 8: Toxicity probabilities 0.10 0.15 0.30 0.45 0.60 0.75 0.10 0.15 0.30 0.45 0.60 0.75
3 + 3 (3.5) 7.8 22.4 30.6 23.7 10.0 2.1 - - - - - -
CRM 1.1 15.1 60.6 21.6 1.5 0.2 13.5 20.4 39.6 18.4 4.9 3.1
TS 0.9 20.0 58.7 19.3 1.1 0.1 20.4 24.0 27.1 14.4 4.5 9.6
TS() 0.9 15.5 61.4 20.4 1.1 0.6 13.4 20.8 40.2 17.8 4.8 2.9
TS A 0.3 14.5 51.9 24.0 5.4 3.8 22.4 30.1 31.7 13.0 2.3 0.5
Independent TS 20.8 27.1 26.2 16.9 6.9 2.1 17.8 21.7 20.3 16.9 13.3 10.0
Sc. 9: Toxicity probabilities 0.01 0.05 0.08 0.15 0.30 0.45 0.01 0.05 0.08 0.15 0.30 0.45
3 + 3 (0.0) 0.8 2.1 7.9 21.6 30.9 36.8 - - - - - -
CRM 1.9 0.1 0.4 16.1 54.1 27.4 9.8 8.5 10.0 17.0 28.9 25.8
TS 0.5 0.1 0.5 15.5 55.0 28.3 10.1 10.2 12.3 17.8 19.8 29.8
TS() 0.5 0.0 0.5 16.8 53.3 28.8 9.1 8.3 10.0 17.5 28.7 26.3
TS A 0.3 0.0 0.5 13.3 46.7 39.2 10.4 12.3 16.5 22.9 19.9 18.1
Independent TS 19.1 12.5 13.8 18.1 23.3 13.2 15.8 17.0 17.5 17.5 17.7 14.6
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5.2 Maximizing Efficacy Under Toxicity Constraints in Presence of a Plateau
In this set of experiments, we evaluate the performance of the two algorithm introduced in Section 4.2,
TS and TS A, and compare them to the MTA-RA algorithm. We use the experimental setup of Riviere
et al. (2017): several scenarios with K = 6 doses, budget n = 60, θ = 0.35, toxicity and efficacy priors
p0 = [0.02, 0.06, 0.12, 0.20, 0.30, 0.40]
and eff0 = [0.12, 0.20, 0.30, 0.40, 0.50, 0.59].
Furthermore, we use the same parameters for the admissible set and the implementation of MTA-RA as
those chosen by Riviere et al. (2017): ξ = 0.2, c1 = 0.9, c2 = 0.4, and s1 = .2
(
1− In
)
, where I is the
number of samples used so far. These parameters are defined above in the main text.
In Tables 3 and 4 we provide results on several scenarios. We report the percentage of allocation to
each dose, the percentage of recommendation of each dose when n = 60, and the percentage of time
the trials stopped early (E-Stop), estimated over N = 2000 repetitions. Optimal doses are underlined by
a plain line while a dashed line identifies doses whose toxicity is larger than θ. We mark in bold cases
where our algorithms makes the optimal decision (in terms of the percentage of recommendation) more
often than the MTA-RA baseline.
Dose recommendation. Recall that the modeling assumption here is that efficacy increases monoton-
ically in toxicity up to a point and then it plateaus. We present experimental results on several scenarios,
some of which are borrowed from Riviere et al. (2017), on which this plateau assumption is not always
exactly met. In most of these scenarios, TS A outperforms the MTA-RA algorithm.
In scenarios 1 through 4 and in scenarios 12 and 13, there is a plateau of efficacy starting at a
reasonable toxicity: in this case the optimal dose corresponds to the plateau breakpoint. Our algorithms
make the optimal decision compared to MTA-RA consistently: TS 4 out of 6 times and TS A 5 out of 6
times. In scenarios 5 and 6 the plateau of efficacy starts when the toxicity is already too high, hence the
optimal dose is before than the plateau. In scenario 5, TS A and TS both outperform MTA-RA, while
on scenario 6 MTA-RA has a slight advantage over TS.
In scenario 7 and 8 there is no true plateau of efficacy, however in both cases there exists a “break-
point” (underlined) after which the efficacy is increasing very slowly while the toxicity is increasing
significantly. This breakpoint can thus be argued to be a good trade-off between efficacy and toxicity
and should be investigated in further phases. In these two scenarios TS A identifies this pseudo-optimal
dose more often than MTA-RA, while TS has a slightly worse performance.
Lastly, we study the case when there is no clear optimal or near-optimal dose, i.e. scenarios 9-11. In
scenario 9 wherein most doses, including the entire quasi-plateau, are too toxic, we would like to stop
early or at most recommend dose 1 (the only dose meeting the toxicity constraint but whose efficacy is
not very high). Under this interpretation, TS and TS A outperform MTA-RA. Note that our algorithms
most often either stop early or recommend dose 1, while in comparison MTA-RA recommends the toxic
dose 2 a large fraction (0.332) of the time. In scenarios 10 and 11 in which all doses are either too toxic
or ineffective a good algorithm would stop early with no recommendation. TS A makes this optimal
decision more often than MTA-RA in both scenarios and TS in one of the two scenarios.
Dose allocation. While TS and TS A have lower allocation percentage at the optimal (underlined)
dose compared to MTA-RA, the addition of the admissible set A to the Thompson Sampling method
consistently reduces the percentage of dose allocation at doses that are too toxic. Furthermore, TS A
is more cautious in allocating higher doses compared to MTA-RA. Our experiments notably reveal
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Table 3: Efficacy under MTD constraint results.
Algorithm E-Stop Recommended Allocated
1 2 3 4 5 6 1 2 3 4 5 6
Sc. 1: Toxicity probabilities 0.01 0.05 0.15 0.2 0.45 0.6 0.01 0.05 0.15 0.2 0.45 0.6
Sc. 1: Efficacy probabilities 0.1 0.35 0.6 0.6 0.6 0.6 0.1 0.35 0.6 0.6 0.6 0.6
MTA-RA 0.4 0.4 7.0 54.9 29.1 7.4 0.7 7.1 14.2 37.9 24.9 12.9 2.5
TS 0.9 0.1 9.7 57.7 27.0 4.2 0.4 10.6 18.4 31.9 23.8 10.0 4.4
TS A 0.9 0.3 9.6 59.4 26.1 3.5 0.3 10.7 20.7 35.7 23.9 7.3 0.9
Sc. 2: Toxicity probabilities 0.005 0.01 0.02 0.05 0.1 0.15 0.005 0.01 0.02 0.05 0.1 0.15
Sc. 2: Efficacy probabilities 0.001 0.1 0.3 0.5 0.8 0.8 0.001 0.1 0.3 0.5 0.8 0.8
MTA-RA 1.9 0.0 0.1 1.6 05.1 55.0 36.2 5.2 5.6 7.5 11.4 36.7 31.7
TS 0.7 0.0 0.0 0.5 4.6 56.6 37.4 5.9 6.6 9.3 16.9 32.5 28.1
TS A 2.2 0.0 0.1 1.6 5.0 55.8 35.2 5.9 6.8 10.9 17.9 31.8 24.5
Sc. 3: Toxicity probabilities 0.01 0.05 0.1 0.25 0.5 0.7 0.01 0.05 0.1 0.25 0.5 0.7
Sc. 3: Efficacy probabilities 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
MTA-RA 0.4 51.5 26.4 12.5 6.8 2.2 0.2 38.2 24.8 16.6 12.9 6.1 0.9
TS 0.1 53.9 24.8 12.1 7.9 1.1 0.2 24.1 22.7 23.8 19.0 7.2 3.1
TS A 0.5 53.7 26.4 10.4 8.2 0.7 0.1 26.6 25.1 24.8 17.7 4.8 0.5
Sc. 4: Toxicity probabilities 0.01 0.02 0.05 0.1 0.2 0.3 0.01 0.02 0.05 0.1 0.2 0.3
Sc. 4: Efficacy probabilities 0.25 0.45 0.65 0.65 0.65 0.65 0.25 0.45 0.65 0.65 0.65 0.65
MTA-RA 0.2 1.8 13.2 49.0 21.7 8.5 5.7 9.5 17.7 31.6 20.6 13.9 6.6
TS 0.2 1.8 15.7 45.8 18.0 10.8 7.8 12.1 16.8 23.1 21.6 16.5 9.8
TS A 0.2 2.4 15.0 49.1 20.3 9.8 3.3 13.2 19.3 25.5 21.8 14.1 5.8
Sc. 5: Toxicity probabilities 0.1 0.2 0.25 0.4 0.5 0.6 0.1 0.2 0.25 0.4 0.5 0.6
Sc. 5: Efficacy probabilities 0.3 0.4 0.5 0.7 0.7 0.7 0.3 0.4 0.5 0.7 0.7 0.7
MTA-RA 1.4 9.0 13.3 25.9 40.6 8.3 1.5 15.5 19.1 24.9 26.7 9.9 2.4
TS 5.8 8.4 24.4 40.0 18.9 2.4 0.3 20.8 27.3 24.4 13.0 5.5 3.3
TS A 6.9 16.7 30.6 30.6 14.4 0.8 0.0 25.9 33.8 22.8 8.6 1.8 0.2
Sc. 6: Toxicity probabilities 0.1 0.3 0.35 0.4 0.5 0.6 0.1 0.3 0.35 0.4 0.5 0.6
Sc. 6: Efficacy probabilities 0.3 0.4 0.5 0.7 0.7 0.7 0.3 0.4 0.5 0.7 0.7 0.7
MTA-RA 4.3 11.2 24.3 24.6 28.9 5.4 1.3 17.9 24.2 23.7 20.7 7.7 1.7
TS 8.4 17.8 41.9 22.5 8.1 1.1 0.3 29.6 30.4 16.9 8.3 4.0 2.4
TS A 9.4 28.5 43.6 14.2 4.0 0.3 0.0 34.5 37.2 14.3 3.9 0.6 0.1
Sc. 7: Toxicity probabilities 0.03 0.06 0.1 0.2 0.4 0.5 0.03 0.06 0.1 0.2 0.4 0.5
Sc. 7: Efficacy probabilities 0.3 0.5 0.52 0.54 0.55 0.55 0.3 0.5 0.52 0.54 0.55 0.55
MTA-RA 0.1 8.6 45.5 25.1 13.7 5.7 1.3 16.1 31.5 22.8 17.0 9.9 2.5
TS 0.7 10.3 43.7 22.2 16.3 5.7 1.2 17.5 22.7 23.2 20.6 10.3 4.9
TS A 0.4 11.4 47.8 22.8 13.3 4.2 0.2 19.8 26.9 26.1 19.0 6.6 1.2
Sc. 8: Toxicity probabilities 0.02 0.07 0.13 0.17 0.25 0.3 0.02 0.07 0.13 0.17 0.25 0.3
Sc. 8: Efficacy probabilities 0.3 0.5 0.7 0.73 0.76 0.77 0.3 0.5 0.7 0.73 0.76 0.77
MTA-RA 0.1 1.1 10.2 39.0 24.4 16.8 8.4 9.3 15.8 28.8 22.6 15.7 7.8
TS 0.3 1.3 11.1 36.8 24.2 16.1 10.2 12.1 17.4 24.1 21.9 15.0 9.1
TS A 0.3 1.8 13.2 45.6 24.1 11.4 3.7 14.2 22.2 28.6 21.0 10.3 3.4
17
Table 4: Efficacy under MTD constraint results (continued).
Algorithm E-Stop Recommended Allocated
1 2 3 4 5 6 1 2 3 4 5 6
Sc. 9: Toxicity probabilities 0.25 0.43 0.50 0.58 0.64 0.75 0.25 0.43 0.50 0.58 0.64 0.75
Sc. 9: Efficacy probabilities 0.3 0.4 0.5 0.6 0.61 0.63 0.3 0.4 0.5 0.6 0.61 0.63
MTA-RA 18.8 40.0 33.2 7.0 0.9 0.1 0.1 32.0 30.3 13.6 4.3 1.0 0.1
TS 49.0 37.3 12.4 1.1 0.2 0.0 0.0 29.0 13.7 4.5 1.9 1.1 0.8
TS A 50.5 39.8 9.1 0.5 0.1 0.0 0.0 31.2 14.6 3.3 0.4 0.0 0.0
Sc. 10: Toxicity probabilities 0.05 0.1 0.25 0.55 0.7 0.9 0.05 0.1 0.25 0.55 0.7 0.9
Sc. 10: Efficacy probabilities 0.01 0.02 0.05 0.35 0.55 0.7 0.01 0.02 0.05 0.35 0.55 0.7
MTA-RA 91.7 0.5 0.5 2.3 4.8 0.1 0.0 0.6 0.7 1.3 4.4 1.1 0.2
TS 61.9 12.1 2.5 1.8 19.7 1.8 0.1 3.8 8.9 16.3 6.3 1.9 0.9
TS A 94.1 0.2 0.1 1.3 4.3 0.1 0.0 0.5 0.6 1.4 2.9 0.5 0.0
Sc. 11: Toxicity probabilities 0.5 0.6 0.69 0.76 0.82 0.89 0.5 0.6 0.69 0.76 0.82 0.89
Sc. 11: Efficacy probabilities 0.4 0.55 0.65 0.65 0.65 0.65 0.4 0.55 0.65 0.65 0.65 0.65
MTA-RA 90.1 9.6 0.3 0.1 0.0 0.0 0.0 7.2 2.0 0.5 0.1 0.0 0.0
TS 99.8 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0
TS A 99.5 0.5 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0
Sc. 12: Toxicity probabilities 0.01 0.02 0.05 0.1 0.25 0.5 0.01 0.02 0.05 0.1 0.25 0.5
Sc. 12: Efficacy probabilities 0.05 0.25 0.45 0.7 0.7 0.7 0.05 0.25 0.45 0.7 0.7 0.7
MTA-RA 1.0 0.2 1.3 8.9 52.8 29.4 6.4 5.8 7.6 14.6 35.9 24.9 10.2
TS 0.7 0.0 0.6 10.0 57.0 27.7 4.0 7.7 10.4 17.9 32.2 21.9 9.3
TS A 1.7 0.0 1.3 10.0 56.0 26.8 4.2 7.5 11.3 19.5 32.1 21.6 6.4
Sc. 13: Toxicity probabilities 0.01 0.05 0.1 0.2 0.3 0.5 0.01 0.05 0.1 0.2 0.3 0.5
Sc. 13: Efficacy probabilities 0.05 0.1 0.2 0.35 0.55 0.55 0.05 0.1 0.2 0.35 0.55 0.55
MTA-RA 14.9 0.7 1.8 5.6 17.0 50.3 9.7 6.4 7.4 11.1 18.7 30.7 10.8
TS 8.6 0.5 1.8 6.7 37.7 39.0 5.6 9.1 11.5 17.5 26.3 18.6 8.4
TS A 17.3 0.5 1.3 7.4 31.6 37.5 4.3 7.2 9.1 16.7 26.8 18.1 4.7
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that the fraction of allocation to doses whose toxicity is larger than θ (that are underlined with a dashed
line) is always smaller for TS A than for MTA-RA. Hence, not only is TS A very good in terms of
recommending the right dose, it also manages to avoid too-toxic doses more consistently.
6. Revisiting the Treatment versus Experimentation Trade-off
Ideally, a good design for MTD identification should be supported by a control of both the error prob-
ability en = P(kˆn 6= k∗) and the number of sub-optimal selections E[Nk(n)] for k 6= k∗. These
two quantities are respectively useful to check whether the design achieves a good identification of the
optimal dose and whether a large number of patients have been treated with the optimal dose.
For classical bandits (in which k∗ is the arm with largest mean instead of the MTD), those two
performance measures are known to be antagonistic. Indeed, Bubeck et al. (2011) shows that the smaller
the regret (a quantity that can be related to the number of sub-optimal selections), the larger the error
probability. Such a trade-off may also exist for the MTD identification problem. However, the precise
statement of such a result would be meaningful for large values of the number of patients n, which is
of little interest for a real clinical trial as it can only involve a small number of patients. In practice, we
showed that adaptations of Thompson Sampling, a bandit design aimed at maximizing rewards, achieve
good performance in terms of both allocation and recommendation.
Still, another natural avenue of research is to investigate the adaptation of bandit designs aimed at
minimizing the error probability. Minimizing the error probability for MTD can be viewed as a variant
of the fixed-budget Best Arm Identification (BAI) problem introduced by Audibert et al. (2010); Bubeck
et al. (2011). In contrast to the standard BAI problem that aims to identify the arm with largest mean
(which would correspond here to the most toxic dose), the focus is on identifying the arm whose mean
is closest to the threshold θ. A state-of-the art fixed-budget BAI algorithm is Sequential Halving (Karnin
et al., 2013), and we propose in Algorithm 6 an adaptation to MTD identification.
Sequential Halving for MTD identification proceeds in phases. In each of the log2(K) phases, all
the remaining doses are allocated the same amount of times to patients and their empirical toxicity based
on these allocations (that is, the average of the toxicity responses) is computed. At the end of each phase
the empirical worst half of the doses is eliminated. For MTD identification, rather than the doses with
the smallest empirical means (as the vanilla Sequential Halving algorithm would do), the doses whose
empirical toxicity are the furthest away from the threshold θ are eliminated. Observe that by design of
the algorithm, the total number of allocated doses is indeed smaller than the prescribed budget n.
Algorithm 1 Sequential Halving for MTD Identification
Input: budget n, target toxicity θ
Initialization: Set of dose levels S0 ← {1, . . . ,K};
for r ← 0 to dlog2(K)e − 1 do
Allocate each dose k ∈ Sr to tr =
⌊
n
|Sr|dlog2(K)e
⌋
patients;
Based on their response compute pˆrk, the empirical toxicity of dose k based on these tr samples;
Compute Sr+1 the set of d|Sr|/2e arms with smallest dˆrk := |θ − pˆrk|
Output: the unique arm in Sdlog2(K)e
Building on the analysis of Karnin et al. (2013), one can establish the following upper bound on the
error probability of Sequential Halving for MTD identification. The proof can be found in Appendix B.
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Theorem 3 The error probability of the SH algorithm is upper bounded as
P
(
kˆn 6= k∗
)
≤ 9 log2K · exp
(
− n
8H2(p) log2K
)
,
where H2(p) := maxk 6=k∗ k∆−2[k] where ∆k = |pk − θ| − |pk∗ − θ| and ∆[1] ≤ ∆[2] ≤ · · · ≤ ∆[K].
A consequence of Theorem 3 is that in a trial involving more than n = 8H2(p) log2K log (9 log2(K)/δ)
patients, Sequential Halving is guaranteed to identify the MTD with probability larger than 1− δ. How-
ever, this number is typically much larger than the number of patients involved in a medical study. Indeed
the complexity termH2(p) may be quite large, when some doses have a distance to the threshold θ which
is very close to the closest distance |pk∗ − θ|.
An important shortcoming of Sequential Halving is that due to the uniform exploration within each
phase each dose is selected at least n/(K log2(K)) times, even the largest, possibly harmful ones. This
is highly unethical in a clinical trial without prior knowledge that too-toxic (or too ineffective) doses
have already been eliminated. This problem of allocating too extreme doses is likely to be shared by
adaptations of any other BAI algorithm, that are expected to select all the arms a linear number of time.
For example, the APT algorithm proposed by Locatelli et al. (2016) to identify all arms with mean above
a threshold θ using a fixed budget n also selects all arms a linear number of time.
To overcome this problem, an interesting avenue of research would be to try to incorporate mono-
tonicity assumptions in BAI algorithms. Garivier et al. (2017) recently proposed such an algorithm
but in the fixed confidence setting: given a risk parameter δ, the goal is identify a dose kˆτ such that
P(kˆτ 6= k∗) ≤ δ, using as few samples τ as possible. Note that in this setting, the stopping rule τ is
random, which would require a clinical trial based on an adaptatively chosen number of patients.
7. Conclusion
Motivated by the literature on multi-armed bandit models, we advocated the use of the powerful Thomp-
son Sampling principle for dose finding studies. This Bayesian randomized algorithm can be used in
different contexts as it can leverage different prior information about the doses. For increasing toxicities
and increasing or plateau efficacies, we proposed variants of Thompson Sampling, notably the TS A
algorithm that often outperforms our baselines in terms of recommendation of the optimal dose, while
significantly reducing the allocation to doses with high toxicity.
We provided theoretical guarantees for the simplest version of Thompson Sampling based on in-
dependent uniform priors on each dose toxicity, but advocated the use of more sophisticated priors for
practical dose finding studies. We believe that finding a practical design for which we can also establish
non-trivial finite-time performance guarantees is a crucial research question.
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Appendix A. Analysis of Independent Thompson Sampling: Proof of Theorem 1
Fix a sub-optimal arm k. Several cases need to be considered depending on the relative position of pk
and pk∗ with respect to the threshold. All cases can be treated similarly and to fix the ideas, we consider
the case pk∗ ≥ θ > pk, which is illustrated below. In that case d∗k = 2θ − pk∗ satisfies pk ≤ d∗k ≤ θ.
θ
pk
pk*
dk*
x
y
y'
Let x, y ∈]0, 1[2 be such that pk < x < y < dk∗ , that will be chosen later. Define y′ = 2θ − y > θ
the symmetric of y with respect to the threshold (see the above illustration). We denote by µˆk(t) the
empirical mean of the toxicity responses gathered from dose k up to the end of round t and recall θk(t) is
the sample from the Beta posterior on pk after t rounds that is used in the Thompson Sampling algorithm.
Inspired by the analysis of Agrawal and Goyal (2013a), we introduce the following two events, that are
quite likely to happen when enough samples of arm k have been gathered:
Eµk (t) = (µˆk(t) ≤ x) and Eθk(t) = (θk(t) ≤ y) .
The expected number of allocations of dose k is then decomposed in the following way
E[Nk(T )] =
T−1∑
t=0
P
(
Dt+1 = k,E
µ
k (t), E
θ
k(t)
)
︸ ︷︷ ︸
(I)
+
T−1∑
t=0
P
(
Dt+1 = k,E
µ
k (t), E
θ
k(t)
)
︸ ︷︷ ︸
(II)
+
T−1∑
t=0
P
(
Dt+1 = k,E
µ
k (t)
)
︸ ︷︷ ︸
(III)
Terms (II) and (III) are easily controlled using some concentration inequalities and the so-called Beta-
Binomial trick, that is the fact that the CDF of a Beta distribution with parameters a and b, FBetaa,b , is
related to the CDF of a binomial distribution with parameter n, x, FBn,x, in the following way:
FBetaa,b (x) = 1− FBa+b−1,x(a− 1).
Term (III) is very small as arm k is unlikely to be drawn often while its empirical mean falls above
x > pk and term (II) grows logarithmically with T . More precisely, it can be shown using Lemma 3 and
4 in Agrawal and Goyal (2013a) that
(II) ≤ log(T )
d(x, y)
+ 1 and (III) ≤ 1
d(x, y)
+ 1.
The tricky part of the analysis is to control term (I), that is to upper bound the number of selections of
dose k when both the empirical mean and the Thompson sample for dose k fall close to the true mean
pk. For this purpose, one can prove a counterpart of Lemma 1 in Agrawal and Goyal (2013a) that relates
the probability of selecting dose k to that of selecting the MTD k∗.
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Lemma 4 Define py(t) := P (θk∗(t) ∈ [y, y′]|Ft), where Fs is the filtration generated by the observa-
tion up to the end of round s. Then
P
(
Dt+1 = k|Eθk(t+ 1),Ft
)
≤ 1− py(t)
py(t)
P
(
Dt+1 = k
∗|Eθk(t+ 1),Ft
)
.
Proof The proof is inspired of that of Lemma 1 in Agrawal and Goyal (2013a). We introduce the event
in which the Thompson sample for dose k is the closest to the threshold θ among all sub-optimal doses:
Mk(t) = {|θ − θk(t)| ≥ |θ − θ`(t)|∀` 6= k∗}.
On the one hand, one has
P
(
Dt+1 = k
∗|Eθk(t+ 1),Ft
)
≥ P
(
Dt+1 = k
∗,Mk(t)|Eθk(t+ 1),Ft
)
≥ P
(
θk∗(t) ∈ [y, y′],Mk(t)|Eθk(t+ 1),Ft
)
= py(t)× P
(
Mk(t)|Eθk(t+ 1),Ft
)
.
On the other hand, it holds that
P
(
Dt+1 = k|Eθk(t+ 1),Ft
)
≤ P
(
θk∗(t) /∈ [y, y′],Mk(t)|Eθk(t+ 1),Ft
)
= (1− py(t))× P
(
Mk(t)|Eθk(t+ 1),Ft
)
.
Combining the two inequalities yields Lemma 4.
Using the same steps as Agrawal and Goyal (2013a) yields an upper bound on the first term:
(I) ≤
T−1∑
j=1
E
[
1
py(τj)
− 1
]
,
where τj is the time instant at which dose k is selected for the j-th time. The expectation of 1/py(τj)
can be explicitly written
E
[
1
py(τj)
]
=
j∑
s=0
fBj,pk∗ (s)
P (y ≤ Xs+1,j−s+1 ≤ y′)
where fBn,x stands for the pdf of a Binomial distribution and Xa,b denotes a random variable that has
a Beta(a, b) distribution. The following lemma is crucial to finish the proof. This original result was
specifically obtained for the MTD identification problem and is needed to control the probability that a
Beta distributed random variable fall inside an interval, that is P (y ≤ Xs+1,j−s+1 ≤ y′).
Lemma 5 There exists j0 such that, for all j ≥ j0,
∀s ∈ {0, . . . , j}, P (y ≤ Xs+1,j−s+1 ≤ y′) ≥ 1
2
min
{
P (Xs+1,j+s+1 ≥ y) ;P
(
Xs+1,j+s+1 ≤ y′
)}
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Using Lemma 5 and the Beta-Binomial trick, one can write, for j ≥ j0,
E
[
1
py(τj)
]
≤
j∑
s=0
2fBj,pk∗ (s)
P (Xs+1,j+s+1 ≥ y) +
j∑
s=0
2fBj,pk∗ (s)
P (Xs+1,j+s+1 ≤ y′)
=
j∑
s=0
2fBj,pk∗ (s)
FBj+1,y(s)
+
j∑
s=0
2fBj,pk∗ (s)
1− FBj+1,y′(s)
=
j∑
s=0
2fBj,pk∗ (s)
FBj+1,y(s)
+
j∑
s=0
2fBj,1−pk∗ (s)
FBj+1,1−y′(s)
, (9)
where the last equality relies on the following properties of the Binomial distribution
fBn,x(s) = f
B
n,1−x(n− s) and FBn,x(s) = 1− Fn,1−x(n− s− 1)
and a change of variable in the second sum.
Now the following upper bound can be extracted from the proof of Lemma 3 in Agrawal and Goyal
(2013a).
Lemma 6 Fix u and v such that u < v and let ∆ = v − u. Then
j∑
s=0
fBj,v(s)
FBj,u(s)
≤
{
1 + 3∆ if j < 8/∆,
1 + Θ
(
e−∆2j/2 + 1
(j+1)∆2
e−2∆2j + 1
e∆
2j/4−1
)
else.
Each of the two sums in (9) can be upper bounded using Lemma 6. Letting ∆1 = pk∗ − y and
∆2 = y
′ − pk∗ , one obtains
(I) ≤
j0∑
j=1
E
[
1
py(τj)
]
− j0 + 24
∆21
+
24
∆22
+ C
T−1∑
j=0
[
e−∆
2
1j/2 +
1
(j + 1)∆21
e−2∆
2
1j +
1
e∆
2
1j/4 − 1
]
+ C
T−1∑
j=0
[
e−∆
2
2j/2 +
1
(j + 1)∆22
e−2∆
2
2j +
1
e∆
2
2j/4 − 1
]
,
which is a constant (as the series have a finite sum) that only depends on y, θ and pk∗ (through y′ and the
gaps ∆1 and ∆2 defined above).
Putting things together, we proved that for every x and y satisfying pk < x < y < dk∗ , the number
of selections of dose k is upper bounded as
E[Nk(T )] ≤ 1
d(x, y)
log(T ) + Cx,y,θ,p
for some constant that depends on the toxicity probabilities, the threshold θ and the choice of x and y.
Now, picking x and y such that d(x, y) = d(pk,dk∗ )1+ yield the result.

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Proof of Lemma 5. The proof uses the two equalities below
P
(
y ≤ Xs+1,j−s+1 ≤ y′
)
= P (Xs+1,j−s+1 ≥ y)− P
(
Xs+1,j−s+1 ≥ y′
)
(10)
P
(
y ≤ Xs+1,j−s+1 ≤ y′
)
= P
(
Xs+1,j−s+1 ≤ y′
)− P (Xs+1,j−s+1 ≤ y) , (11)
as well as the Sanov inequalities: if Sn,x is a binomial distribution with parameters n and x, then
e−nkl(k/n,x)
n+ 1
≤ P (Sn,x ≥ k)
≤ e−nkl(k/n,x) if k > xn (12)
e−nkl(k/n,x)
n+ 1
≤ P (Sn,x ≤ k)
≤ e−nkl(k/n,x) if k < xn (13)
We prove the inequality considering 4 cases. We define ymid =
y+y′
2 .
Case 1: s < (j + 1)y Starting from equality (10) and using the Beta-Binomial trick yields
P
(
y ≤ Xs+1,j−s+1 ≤ y′
)
= P (Sj+1,y ≤ s)− P
(
Sj+1,y′ ≤ s
)
.
Using Sanov inequalities, we shall prove that there exists some j1 such that if j ≥ j1,
∀s ≤ (j + 1)y, P (Sj+1,y′ ≤ s) ≤ 1
2
P (Sj+1,y ≤ s) .
As s is smaller than the mean of the two Binomial distributions, by (13) it is sufficient to prove that
∀s ≤ (j + 1)y, e−(j+1)kl
(
s
j+1
,y′
)
≤ 1
2(j + 2)
e
−(j+1)kl
(
s
j+1
,y
)
which in turn is equivalent to
∀s ≤ (j + 1)y, kl
(
s
j + 1
, y′
)
− kl
(
s
j + 1
, y
)
≥ log(2(j + 2))
j + 1
.
As the function in the left-hand side is non-increasing in s, a sufficient condition is that j satisfies
kl
(
y, y′
) ≥ log(2(j + 2))
j + 1
,
which is the case for j superior to some j1. Thus, for j ≥ j1,
P
(
y ≤ Xs+1,j−s+1 ≤ y′
) ≥ 1
2
P (Sj+1,y ≤ s) = 1
2
P (Xs+1,j−s+1 ≥ y) .
Case 2: (j+ 1)y ≤ s ≤ (j+ 1)ymid Starting from equality (10) and using the Beta-Binomial trick
and the upper bound in (13) yields
P
(
y ≤ Xs+1,j−s+1 ≤ y′
) ≥ P (Sj+1,y ≤ s)− e−(j+1)kl( sj+1 ,y′)
≥ P (Sj+1,y ≤ s)− e−(j+1)kl(ymid,y′).
The median of Sj+1,y is b(j + 1)yc or d(j + 1)ye. As s ≤ (j + 1)y, it holds that P (Sj+1,y ≤ s) ≥ 12 .
Therefore, for all j ≥ j2 := ln 4kl(ymid,y′) − 1,
e−(j+1)kl(ymid,y
′) ≤ 1
4
≤ 1
2
P (Sj+1,y ≤ s) .
Therefore if j ≥ j2, P (y ≤ Xs+1,j−s+1 ≤ y′) ≥ 12P (Xs+1,j−s+1 ≥ y).
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Case 3: (j+1)ymid ≤ s ≤ (j+1)y′ Starting from equality (11) and using the Beta-Binomial trick
and the upper bound in (12) yields
P
(
y ≤ Xs+1,j−s+1 ≤ y′
) ≥ P (Sj+1,y′ ≥ s)− e−(j+1)kl( sj+1 ,y)
≥ P (Sj+1,y′ ≥ s)− e−(j+1)kl(ymid,y).
The median of Sj+1,y′ is b(j+ 1)y′c or d(j+ 1)y′e. As s ≤ (j+ 1)y′, it holds that P
(
Sj+1,y′ ≥ s
) ≥ 12 .
Therefore, for all j ≥ j3 := ln 4kl(ymid,y) − 1,
e−(j+1)kl(ymid,y) ≤ 1
4
≤ 1
2
P
(
Sj+1,y′ ≥ s
)
.
Therefore if j ≥ j3, P (y ≤ Xs+1,j−s+1 ≤ y′) ≥ 12P (Xs+1,j−s+1 ≤ y′).
Case 4: s > (j + 1)y′ Starting from equality (11) and using the Beta-Binomial trick yields
P
(
y ≤ Xs+1,j−s+1 ≤ y′
)
= P
(
Sj+1,y′ ≥ s
)− P (Sj+1,y ≥ s) .
Using Sanov inequalities, we shall prove that there exists some j4 such that if j ≥ j4,
∀s ≥ (j + 1)y′, P (Sj+1,y ≥ s) ≤ 1
2
P
(
Sj+1,y′ ≥ s
)
.
As s is larger than the mean of the two Binomial distributions, by (12) it is sufficient to prove that
∀s ≥ (j + 1)y′, e−(j+1)kl
(
s
j+1
,y
)
≤ 1
2(j + 2)
e
−(j+1)kl
(
s
j+1
,y′
)
which in turn is equivalent to
∀s ≥ (j + 1)y′, kl
(
s
j + 1
, y
)
− kl
(
s
j + 1
, y′
)
≥ log(2(j + 2))
j + 1
.
As the function in the left-hand side is non-decreasing in s, a sufficient condition is that j satisfies
kl
(
y′, y
) ≥ log(2(j + 2))
j + 1
,
which is the case for j superior to some j4. Thus, for j ≥ j4,
P
(
y ≤ Xs+1,j−s+1 ≤ y′
) ≥ 1
2
P
(
Sj+1,y′ ≥ s
)
=
1
2
P
(
Xs+1,j−s+1 ≤ y′
)
.
Conclusion Letting j0 = max(j1, j2, j3, j4), for all j ≥ j0, for every s ∈ {0, . . . , j},
P
(
y ≤ Xs+1,j−s+1 ≤ y′
) ≥ 1
2
min
{
P (Xs+1,j+s+1 ≥ y) ;P
(
Xs+1,j+s+1 ≤ y′
)}

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Appendix B. Analysis of Sequential Halving: Proof of Theorem 3
Recall dˆrk = |θ − pˆtk| is the empirical distance from the toxicity of dose k to the threshold, where pˆrk is
the empirical average of the toxicity responses observed for dose k during phase r (based on tr samples).
The central element of the proof is Lemma 7 below, that controls the probability that dose k seems to
be be closer to the threshold than the MTD k∗ in phase r. Its proof is more sophisticated than that of
Lemma 4.2 in Karnin et al. (2013) as several cases need to be considered.
Lemma 7 Assume that the arm closest to θ was not eliminated prior to round r. Then for any arm
k ∈ Sr,
P(dˆrk∗ > dˆrk) ≤ 3 exp
(
− tr
2
∆2k
)
. (14)
Proof For the means pk∗ and pk let pˆrk∗ and pˆ
r
k denote their expected rewards in round r, respectively.
We will first derive a probability bound which does not depend on the ordering of pk and pk∗ w.r.t. θ,
and then we will do a case analysis of the possible orderings to produce our final bound.
The error event can be decomposed as follows.{
dˆrk∗ > dˆ
r
k
}
=
({pˆk∗,r > θ} ∩ {pˆk,r > θ} ∩ {pˆk∗,r − θ > pˆk,r − θ})
∪ ({pˆk∗,r ≤ θ} ∩ {pˆk,r > θ} ∩ {θ − pˆk∗,r > pˆk,r − θ})
∪ ({pˆk∗,r > θ} ∩ {pˆk,r ≤ θ} ∩ {pˆk∗,r − θ > θ − pˆk,r})
∪ ({pˆk∗,r ≤ θ} ∩ {pˆk,r ≤ θ} ∩ {θ − pˆk∗,r > θ − pˆk,r})
From there, we distinguish two cases, in which we show the error event is included in a reunion of events
whose probability can be controlled using the Hoeffding’s inequality.
Case 1: pk ≥ θ. In that case, it is very unlikely that {pˆk,r < θ}. Hence, we can isolate that event and
use the previous decomposition to write{
dˆrk∗ > dˆ
r
k
}
⊆
{pˆk,r ≤ θ} ∪ {pˆk∗,r − pˆk,r > 0} ∪ {pˆk,r + pˆk∗,r < 2θ} .
When pk ≥ θ, irrespective of the position of pk∗ with respect to θ, one can justify that pk > θ, pk∗−pk <
0 and pk+pk∗ > 2θ (as pk ≥ max(pk∗ , 2θ−pk∗) because k is a suboptimal arm larger than the threshold).
Therefore, the above three events are unlikely. More precisely, using Hoeffding’s inequality yields
P(dˆrk∗ > dˆrk) ≤ P(pˆk,r ≤ θ) + P(pˆk∗,r − pˆk,r > 0) + P(pˆk∗,r + pk,r < 2θ)
≤ exp (−2tr(θ − pk)2}+ exp{− tr
2
(pk∗ − pk)2
}
+ exp
{
− tr
2
(pk∗ + pk − 2θ)2
)
≤ 3 exp
(
− tr
2
min
{
(pk − θ)2, (pk − pk∗)2, (pk∗ + pk − 2θ)2
})
= 3 exp
(
− tr
2
min
{
(pk − pk∗)2, (pk − (2θ − pk∗))2
})
Equation (14) follows as ∆2k = min
{
(pk − pk∗)2, (pk − (2θ − pk∗))2
}
.
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Case 2: pk ≤ θ. In that case, the unlikely event is {pˆk,r > θ} and we write{
dˆrk∗ > dˆ
r
k
}
⊆ {pˆk,r > θ} ∪ {pˆk,r − pˆk∗,r > 0} ∪ {pˆk,r + pˆk∗,r > 2θ} .
When pk < θ, irrespective of the position of pk∗ with respect to θ, one can justify that pk < θ, pk−pk∗ <
0 and pk + pk∗ < 2θ (using the fact that pk ≤ min(pk∗ , 2θ − pk∗)). Then from Hoeffding’s inequality,
P(dˆrk∗ > dˆrk) ≤ P(pˆk,r > θ) + P(pˆk,r − pˆk∗,r > 0) + P(pˆk∗,r + pk,r > 2θ)
≤ exp (−2tr(θ − pk)2}+ exp{− tr
2
(pk∗ − pk)2
}
+ exp
{
− tr
2
(2θ − pk∗ − pk)2
)
≤ 3 exp
(
− tr
2
min
{
(θ − pk)2, (pk∗ − pk)2, (2θ − pk∗ − pk)2
})
= 3 exp
(
− tr
2
min
{
(pk∗ − pk)2, ((2θ − pk∗)− pk)2
})
which proves Equation 14 as ∆2k = min
{
(pk∗ − pk)2, ((2θ − pk∗)− pk)2
}
.
Building on Lemma 7, the next step is to control the probability that the MTD is eliminated in phase
r. The proof bears strong similarities with that of Lemma 4.3 in Karnin et al. (2013). It is given below
for the sake of completeness.
Lemma 8 The probability that the MTD is eliminated at the end of phase r is at most
9 exp
(
− n
8 log2K
· ∆
2
kr
kr
)
where kr = K/2r+2.
The end of the proof of Theorem 3 is identical to than of Theorem 4.1 in Karnin et al. (2013), except
that it uses our Lemma 8. We repeat the argument below with the appropriate modifications. Observe
that if the algorithm recommends a wrong dose, the MTD must have been eliminated in one of t log2(K)
phases. Using Lemma 8 and a union bound yields the upper bound
P
(
kˆn 6= k∗
)
≤ 9
log2 K∑
r=1
exp
(
− n
8 log2K
· ∆
2
kr
kr
)
≤ 9 log2K · exp
(
− n
8 log2K
· 1
maxk k∆
−2
k
)
≤ 9 log2K · exp
(
− n
8H2(p) log2K
)
,
which concludes the proof.
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Proof of Lemma 8 Define S′r as the set of arms in Sr, excluding the 14 |Sr| = K/2r+2 arms with means
closest to θ. If the MTD k∗ is eliminated in round r, it must be the case that at least half the arms of
Sr (i.e., 12 |Sr| = K/2r+1 arms) have their empirical average closer to θ than its empirical average. In
particular, the empirical means of at least 13 |S′r| = K/2r+2 of the arms in S′r must be closer to θ than that
of the k∗ at the end of round r. Letting Nr denote the number of arms in S′r whose empirical average is
closer to θ than that of the optimal arm, we have by Lemma 7:
E[Nr] =
∑
k∈S′r
P(dˆrk < dˆrk∗)
≤
∑
k∈S′r
3 exp
(
− tr
2
∆2k
)
≤ 3
∑
k∈S′r
exp
(
−1
2
∆2k ·
n
|Sr| log2K
)
≤ 3|S′r|max
k∈S′r
exp
(
−1
2
∆2k ·
2rn
K log2K
)
≤ 3|S′r| exp
(
− n
8 log2K
· ∆
2
kr
kr
)
Where the last inequality follows from the fact that there are at least kr − 1 arms that are not in S′r with
average reward closer to θ than that of any arm in S′r. We now apply Markov’s inequality to obtain
P
(
Nr >
1
3
|S′r|
)
≤ 3E[Nr]/|S′r|
≤ 9 exp
(
− n
8 log2K
· ∆
2
kr
kr
)
,
and the lemma follows.
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